‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up
Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.
Protecting Your Biotech: Understanding the Risks of Compounded GLP-1s
With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it’s no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly Lawsuit
This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Why Novo Nordisk Is Dropping Its Collaboration with Hims & Hers
Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.